Eli Lilly & Company OPEB

Eli Lilly & Company OPEB

Eli Lilly & Company OPEB is an asset owner managing health plan assets on behalf of the pharmaceutical company's post-employment benefit obligations. The entity has been overseen for over 20 years by Susan Ridlen, who served as Chief Investment Officer and Assistant Treasurer until her departure in 2025. Jane A. Kirkham holds a role on the Fund Advisory Committee, which advises on investment governance. The trust pursues a growth capital strategy across multiple asset classes. Public filings and the firm's investment approach suggest allocations to private equity, growth equity, and possibly venture capital. The portfolio likely includes direct co-investments alongside external GPs, though specific holdings are not publicly disclosed. The geographic footprint is primarily domestic (United States), with possible exposure to international markets through fund commitments. Team size and total deployment figures are not publicly disclosed. The fund operates as a standalone trust within the broader Eli Lilly corporate structure. Adjacent vehicles include the Lilly Endowment Inc., a philanthropic foundation that is separately governed and often associated with the Lilly family legacy (per public record). Recent activity: the trust continued its growth capital deployment through private market funds and co-investments, though specific deal terms are confidential. The OPEB trust's structural differentiator lies in its mandate. Unlike most corporate pension plans that favor fixed-income and liability-driven strategies, this entity pursues growth capital — a choice that aligns with the long-duration nature of post-employment benefit obligations. The trust's governance structure, with an advisory committee and outsourced investment management, is distinct from the typical in-house corporate pension team.